Back to Search
Start Over
Impella RP for Patients with Acute Right Ventricular Failure and Cardiogenic Shock: A Subanalysis from the IMP-IT Registry.
- Source :
- Journal of Personalized Medicine; Sep2022, Vol. 12 Issue 9, pN.PAG-N.PAG, 10p
- Publication Year :
- 2022
-
Abstract
- The use of percutaneous right ventricular assist devices (pRVADs) to support patients with right ventricular (RV)-predominant cardiogenic shock (CS) refractory to optimal medical therapy is increasing progressively, and the Impella RP is the first FDA-approved pRVAD in such a clinical scenario. The aim of the present study is to report the outcomes of patients treated with Impella RP in the IMP-IT (IMPella Mechanical Circulatory Support Device in Italy) registry, a multicenter registry that evaluated the trends in use and clinical outcomes of the Impella in the setting of CS and high-risk percutaneous coronary intervention in Italy. A total of 15 patients who received Impella RP were enrolled. In 40% of the patients, the main cause was ST-segment elevation myocardial infarction. A total of 40% of patients required biventricular support with a left Impella. Device-related complications were reported in 46.7% of patients. Overall, the in-hospital mortality was 46.7%, whereas the one-year mortality was 53.3%. The composite rate of all-cause death, heart failure (HF) hospitalization, left ventricular assist device (LVAD) and heart transplant at one year was 60%. The Impella RP has favorable survival outcomes in RV-predominant cardiogenic shock. However, the device-related complications are frequent and should be carefully weighed when considering escalation to Impella RP. [ABSTRACT FROM AUTHOR]
Details
- Language :
- English
- ISSN :
- 20754426
- Volume :
- 12
- Issue :
- 9
- Database :
- Complementary Index
- Journal :
- Journal of Personalized Medicine
- Publication Type :
- Academic Journal
- Accession number :
- 159334641
- Full Text :
- https://doi.org/10.3390/jpm12091481